Asset profile
Etentamig
Multispecific antibody
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 23 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Etentamig: this drug | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Teclistamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| BCD-248 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| CM336 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| GR1803 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | ||
| REGN5459 | Phase 1/2 | Multispecific antibody | BCMA x CD3 | ||
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
2028 (1)
February 2028 (1)
What to watch
2029 (1)
August 2029 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
2033 (2)
2035 (1)
December 2035 (1)
What to watch
2036 (3)
March 2036 (1)
What to watch
September 2036 (1)
What to watch
October 2036 (1)
What to watch
2040 (1)
September 2040 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.